TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
25 April 2024 - 6:05AM
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage
biopharmaceutical company focused on the development of T cell
receptor (TCR)-engineered T cell therapies (TCR-T) for the
treatment of patients with cancer, today announced the
acceptance of two abstracts for poster presentation at the upcoming
2024 American Society of Clinical Oncology (ASCO) Annual Meeting
being held May 31 – June 4 in Chicago, IL as well as virtually.
Poster Presentation
Details:
Title: A Phase 1 Trial of
TSC-100 and TSC-101, Engineered T Cell Therapies that Target Minor
Histocompatibility Antigens to Eliminate Residual Disease After
Hematopoietic Cell TransplantationPresenter: Monzr
M. Al Malki, M.D.Abstract Number:
TPS2678Session Title: Developmental Therapeutics –
ImmunotherapySession Date/Time: Saturday, June 1;
9:00 a.m. - 12:00 p.m. Central TimeLocation: Hall
A
Title: Initial Data from a
Phase 1, First-In-Human Clinical Trial for T-Plex, a Multiplexed,
Enhanced T Cell Receptor-Engineered T Cell Therapy (TCR-T) for
Solid TumorsPresenter: Sajeve Thomas,
M.D.Abstract Number: 2542Session
Title: Developmental Therapeutics –
ImmunotherapySession Date/Time: Saturday, June 1;
9:00 a.m. – 12:00 p.m. Central TimeLocation: Hall
A A
copy of the presentation materials will be added to the
“Publications” section of the Company’s website
at tscan.com once presentations have concluded.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical
company focused on the development of T cell receptor
(TCR)-engineered T cell therapies (TCR-T) for the treatment of
patients with cancer. The Company’s lead TCR-T candidates, TSC-100
and TSC-101, are in development for the treatment of patients with
hematologic malignancies to prevent relapse following allogeneic
hematopoietic cell transplantation. The Company is also developing
multiplexed TCR-T candidates for the treatment of various solid
tumors. The Company has developed and continues to expand its
ImmunoBank, the Company’s repository of therapeutic TCRs that
recognize diverse targets and are associated with multiple HLA
types, to provide customized multiplex therapeutic TCR-Ts for
patients with a variety of cancers.
Contacts
Heather SavelleTScan Therapeutics, Inc.VP, Investor
Relations857-399-9840hsavelle@tscan.com
Maghan MeyersArgot
Partners212-600-1902TScan@argotpartners.com
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From Apr 2024 to May 2024
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From May 2023 to May 2024